Catherine Wood's RXRX Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 40.21 M shares of Recursion Pharmaceuticals, Inc. (RXRX) worth $123.45 M, representing 0.96% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in RXRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 13.78 M shares. Largest reduction occurred in Q2 2025, reducing 1.83 M shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Recursion Pharmaceuticals (RXRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Recursion Pharmaceuticals (RXRX) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +2.9 M | Add 7.76% | 40.21 M | $3.07 |
| Q4 2025 | +3.77 M | Add 11.24% | 37.32 M | $4.09 |
| Q3 2025 | +556,868 | Add 1.69% | 33.55 M | $4.88 |
| Q2 2025 | -1.83 M | Reduce 5.25% | 32.99 M | $5.06 |
| Q1 2025 | +2.47 M | Add 7.63% | 34.82 M | $5.29 |
| Q4 2024 | -422,788 | Reduce 1.29% | 32.35 M | $6.76 |
| Q3 2024 | +4.63 M | Add 16.44% | 32.77 M | $6.59 |
| Q2 2024 | +3.56 M | Add 14.46% | 28.14 M | $7.50 |
| Q1 2024 | +3.93 M | Add 19.04% | 24.59 M | $9.97 |
| Q4 2023 | +13.78 M | Add 200.36% | 20.65 M | $9.86 |
| Q3 2023 | +2.14 M | Add 45.12% | 6.88 M | $7.65 |
| Q2 2023 | +1.16 M | Add 32.48% | 4.74 M | $7.47 |
| Q1 2023 | +477,372 | Add 15.40% | 3.58 M | $6.67 |
| Q4 2022 | -260,321 | Reduce 7.75% | 3.1 M | $7.71 |
| Q3 2022 | +627,724 | Add 22.98% | 3.36 M | $10.64 |
| Q2 2022 | -95,076 | Reduce 3.36% | 2.73 M | $6.12 |
| Q1 2022 | +595,150 | Add 26.66% | 2.83 M | $7.16 |
| Q4 2021 | -361,823 | Reduce 13.95% | 2.23 M | $17.13 |
| Q3 2021 | +215,161 | Add 9.05% | 2.59 M | $23.01 |
| Q2 2021 | +2.38 M | New Buy | 2.38 M | $36.50 |
Catherine Wood's Recursion Pharmaceuticals Investment FAQs
Catherine Wood first purchased Recursion Pharmaceuticals, Inc. (RXRX) in Q2 2021, acquiring 2,378,675 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Recursion Pharmaceuticals, Inc. (RXRX) for 20 quarters since Q2 2021.
Catherine Wood's largest addition to Recursion Pharmaceuticals, Inc. (RXRX) was in Q4 2023, adding 20,654,287 shares worth $203.65 M.
According to the latest 13F filing for Q1 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 40,212,769 shares of Recursion Pharmaceuticals, Inc. (RXRX), valued at approximately $123.45 M.
As of the Q1 2026 filing, Recursion Pharmaceuticals, Inc. (RXRX) represents approximately 0.96% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Recursion Pharmaceuticals, Inc. (RXRX) was 40,212,769 shares, as reported at the end of Q1 2026.